




The relative strengths and weaknesses of GT Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GT Biopharma Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of GT Biopharma Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 217%, being 4.0% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	14,056
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,633
Liabilities, Non-Current	0
Other Assets	53
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	5,979
Other Revenues	0
Property and Equipment	0
Research and Development	6,466
Selling, General and Administrative Expense	7,110

Output Variable	Value in 1000 USD
Assets	14,109
Liabilities	6,633
Expenses	13,576
Revenues	0
Stockholders Equity	7,476
Net Income	-7,597
Comprehensive Net Income	-7,597
BaseVar	20,148
ECR before LimitedLiability	84%
Economic Capital Ratio	217%